Bath & Body Works Partnership Boosts Ulta's Assortment but Leaves Core Margin Questions Unanswered

What happened

Ulta Beauty announced a nationwide launch of Bath & Body Works products in over 600 stores and online, expanding its brand assortment under the 'Consumer First Formula' strategy. While this partnership adds a highly popular brand that could drive traffic and incremental sales, it comes at a time when Ulta is wrestling with SG&A deleverage (29.4% of sales in Q3 FY2025) and elevated inventory of $2.7B. The new partnership may help comps but does little to address the structural cost pressures from labor, cloud amortization, and the looming Target shop-in-shop unwind in August 2026. Ulta's filings reveal that promotional intensity and wage investments continue to pressure margins, and the additional brand integration could add further complexity. On balance, the news is a modest positive for demand but does not shift the fundamental challenge of converting sales growth into sustainable profit and cash flow.

Implication

The Bath & Body Works launch is a tactical win for Ulta's assortment depth and relevance, possibly boosting foot traffic and basket size. However, the stock's premium valuation (P/E ~25.5x) already prices in strong demand, and the partnership does not resolve the critical risks: SG&A deleverage, inventory-driven revolver borrowings ($552M), and the Aug-2026 Target unwind. Investors should watch for evidence that the partnership contributes incremental profit above its costs and does not exacerbate promotional intensity. Until Ulta demonstrates operating leverage and cash conversion in upcoming quarters, the risk/reward remains unattractive.

Thesis delta

The Bath & Body Works nationwide launch adds a tangible demand catalyst that modestly supports the bull case for sustained comps, but it does not address the thesis's core concerns of structural SG&A deleverage, working capital strain, and the Target partnership expiration. The investment case still hinges on Ulta's ability to normalize margins and convert sales growth into cash, which the partnership alone cannot guarantee. This shifts the thesis slightly toward expecting the partnership to help comps, but it does not change the WAIT rating until margin and cash flow trends improve.